France 2030 : Lovaltech and Aptar Pharma, Laureates of France 2030
A world-class industrial partner for the LVT-Nexus nasal delivery system:
Lovaltech and Aptar Pharma, a global specialist in pharmaceutical delivery systems, were selected as winners of a France 2030 project call.
The nasal delivery device, which is the third component of the LVT-NEXUS platform alongside the vaccine payload and the LVT-ME muco-excipient, was developed by Aptar Pharma and Lovaltech. It enables simple, needle-free nasal administration.